Large investor in Amicus Therapeutics buys $630k in additional shares
Perceptive Advisors LLC, who already control 10% of shares at Amicus Therapeutics Inc (FOLD), bought 50,000 additional shares of the company’s common stock on Sept 24. At $12.59 per share, Perceptive Advisors LLC paid a total of $629,700 for the new shares.
Already a member?
Login to see your Insider Activity Trade Idea.
Not yet a member?
You can receive four timely bull-put credit spreads each market day by joining our InvestorsKeyhole Daily Trade Alerts Service. Our analysts scour the news looking for unusual options activity, how insiders are trading, and breaking news, and publish trades accordingly.
Become A Member
About Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a global biotechnology company that aims to treat rare and orphan diseases. The company's strategy focuses on global capacity with an international infrastructure, late-stage product acquisition, and biologics manufacturing. Amicus leverages its pharmacological technology to develop treatments for human genetic diseases by targeting mutated proteins. The company utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products.